Antioxidants and cancer therapy II: Quick reference guide

Alternative Medicine Review

Volumn 5, Issue 2, 2000, Pages 152-163

  Lamson, Davis W ^a,b,c   Brignall, Matthew S ^b  

^a Tahoma Clinic   (United States)

^b BASTYR UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BUSULFAN; CYCLOPHOSPHAMIDE; GLUTATHIONE; IFOSFAMIDE; MELATONIN; MELPHALAN; QUERCETIN; RETINOL; SELENIUM; UBIDECARENONE;

ANTIOXIDANT ACTIVITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; DIET SUPPLEMENTATION; HUMAN; NONHUMAN; PHYTOTHERAPY; REVIEW; VITAMIN INTAKE;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS;

EID: 0034090735     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Lamson DW, Brignall MS. Antioxidants in cancer therapy; their actions and interactions with oncologic therapies. Altern Med Rev 1999;4:303-328.
2. Bracke ME, Depypere HT, Boterberg T, et al. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. JNCI 1999;91:354-359.
3. Duchesne GM, Hutchinson LK. Reversible changes in radiation response induced by all-trans retinoic acid. Int J Radiat Oncol Biol Phys 1995;33:875-880.
4. Park TK, Lee JP, Kim SN, et al. Interferon-alpha 2a, 13-cis-retinoic acid and radiotherapy for locally advanced carcinoma of the cervix: a pilot study. Eur J Gynaecol Oncol 1998; 19:35-38.
5. Seifter E, Rettura G, Padawer J. Vitamin A and beta-carotene as adjunctive therapy to tumour excision, radiation therapy and chemotherapy. In: Prasad K, ed. Vitamins Nutrition and Cancer. New York: Karger Press; 1984:2-19.
6. Mills EED. The modifying effect of beta-carotene on radiation and chemotherapy induced oral mucositis. Br J Cancer 1988;57:416-417.
7. Hanck AB. Vitamin C and cancer. Prog Clin Biol Res 1988;259:307-320.
8. Taper HS, Keyeux A, Roberfroid M. Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res 1996;16:499-504.
9. Okunieff P, Suit HD. Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSall murine fibrosarcomas. JNCI 1987;79:377-381.
10. Tewfik FA, Tewfik HH, Riley EF. The influence of ascorbic acid on the growth of solid tumors in mice and on tumor control by X-irradiation. Int J Vitam Nutr Res Suppl 1982;23:257-263.
11. Okunieff P. Interactions between ascorbic acid and the radiation of bone marrow, skin, and tumor. Am J Clin Nutr 1991;54:1281S-1283S.
12. Kagreud A, Peterson HI. Tocopherol in irradiation of experimental neoplasms. Acta Radial Oncol 1981;20:97-100.
13. Hehr T, Hoffmann W, Bamberg M. Role of sodium selenile as an adjuvant in radiotherapy of rectal carcinoma. Med Klin 1997;92:48-49. [Article in German]
14. Lund EL, Quistorff B, Spang-Thomsen M, Kristjansen PEG. Effect of radiation therapy on small-cell lung cancer is reduced by ubiquinone intake. Folia Microbiol 1998;43:505-506.
15. Lissoni P, Meregalli S, Nosetto L, et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology 1996;53:43-46.
16. Maasilta P, Holsti LR, Blomqvist P, et al. N-acetylcysteine in combination with radiotherapy in the treatment of non-small cell lung cancer: a feasibility study. Radiother Oncol 1992;25:192-195.
17. DeMaria D, Falchi AM, Venturino P. Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer. Tumori 1992;78:374-376.
18. Teicher BA, Schwartz JL, Holden SA, et al. In vivo modulation of several anticancer agents by beta-carotene. Cancer Chemother Pharmacol 1994;34:235-241.
19. Taper HS, de Gerlache J, Lans M, et al. Non-toxic potentiation of cancer chemotherapy by combined C and K3 vitamin pre-treatment. Int J Cancer 1987;40:575-579.
20. Vinitha R, Thangaraju M, Sachdanandam P. Effect of administering cyclophosphamide and vitamin E on the levels of tumor-marker enzymes in rats with experimentally induced fibrosarcoma. Jpn J Med Sci Biol 1995;48:145-156.
21. Tobey RA, Tesmer JG. Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan. Cancer Res 1985;45:2567-2571.
22. Kokawa T, Shiota K, Oda K, et al. Coenzyme Q10 in cancer chemotherapy - experimental studies on augmentation of the effects of masked compounds, especially in the combined chemotherapy with immunopotentiators. Gan To Kagaku Ryoho 1983;10:768-774. [Article in Japanese]
23. Takimoto M, Sakurai T, Kodama K, et al. Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy. Gan To Kagaku Ryoho 1982;9:116-121. [Article in Japanese]
24. Musatov SA, Rosenfeld SV, Togo EF, et al. The influence of melatonin on mutagenicity and antitumor action of cytostatic drugs in mice. Vopr Onkol 1997;43:623-627. [Article in Russian]
25. Levy L, Vredevoe DL. The effect of N-acetylcysteine on cyclophosphamide immunoregulation and antitumor activity. Semin Oncol 1983;10:7-16.
26. Harrison EF, Fuquay ME, Hunter HL. Effect of N-acetylcysteine on the antitumor activity of cyclophosphamide against Walker-256 carcinosarcoma in rats. Semin Oncol 1983;10:25-28.
27. Palermo MS, Olabuenaga SE, Giordano M, Isturiz MA. Immunomodulation exerted by cyclophosphamide is not interfered with by N-acetylcysteine. Int J Immunopharmac 1986;8:651-655.
28. Slavik M, Saiers JH. Phase I clinical study of acetylcysteine's preventing ifosfamide-induced hematuria. Semin Oncol 1983;10:62-65.
29. Holoye PY, Duelge J, Hansen RM, et al. Prophylaxis of ifosfamide toxicity with oral acetylcysteine. Semin Oncol 1983;10:66-71.
30. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Am Oncol 1993;4:55-61.
31. Locatelli MC, D'Antonia A, Lablanca R, et al. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori 1993;79:37-39.
32. Scambia G, Ranelletti FO, Panici PB, et al. Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). Gynecol Oncol 1992;45:13-19.
33. Doyle LA, Giangiulo D, Hussain A. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 1989;49:6745-6751.
34. Adwankar M, Banerji A, Ghosh S. Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. Tumori 1991;77:391-394.
35. Thatcher N, Blackledge G, Crowther D. Advanced recurrent squamous cell carcinoma of the head and neck. Cancer 1980;46:1324-1328.
36. Shimpo K, Nagatsu T, Yamada K, et al. Ascorbic acid and adriamycin toxicity. Am J Clin Nutr 1991;54:1298S-1301S.
37. Kurbacher CM, Wagner U, Kolster B, et al. Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett 1996;103:183-189.
38. Wells WW, Rocque PA, Xu DP. Ascorbic acid and cell survival of adriamycin resistant and sensitive MCF-7 breast tumor cells. Free Rad Biol Med 1995;18:699-708.
39. Myers CE, McGuire WP, Liss RH, et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-167.
40. Chinery R, Brockman JA, Peeler MO, et al. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21 via C/ EBP-beta. Nat Med 1997;3:1233-1241.
41. Perez Ripoll EA, Rama BN, Webber MM. Vitamin E enhances the chemotherapeutic effects of adriamycin on human prostatic carcinoma cells in vitro. J Urol 1986;136:529-531.
42. Prasad KN, Edwards-Prasad J, Ramanujam S, Sakamoto A. Vitamin E increases the growth inhibitory and differentiating effects of tumor therapeutic agents on neuroblastoma and glioma cells in culture. Proc Soc Exp Biol Med 1980;164:158-163.
43. Boucher F, Coudray C, Tirard V, et al. Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 1995;11:708-711.
44. Coudray C, Hida H, Boucher F, et al. Modulation by selenium supplementation of lipid peroxidation induced by chronic administration of adriamycin in rats. Nutrition 1995;11:512-516.
45. Shallom J, Juvekar A, Chitnis M. Selenium (Se) cytotoxicity in drug sensitive and drug resistant murine tumour. Cancer Biother 1995;10:243-248.
46. Dimitrov NV, Hay MB, Siew S. Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits. Am J Pathol 1987;126:376-383.
47. Cortes EP, Gupta M, Chou C, et al. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10. Cancer Treat Rep 1978;62:887-891.
48. Iarussi D, Auricchio U, Agretto A, et al. Protective effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in children with acute lymphoblastic leukemia and non-Hodgkin lymphoma. Molec Aspects Med 1994;15:207-212.
49. Okuma K, Furuta I, Ota K. Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin. Gan To Kagaku Ryoho 1984;11:502-508. [Article in Japanese]
50. Shaeffer J, El-Mahdi AM, Nichols RK. Coenzyme Q10 and adriamycin toxicity in mice. Res Commun Chem Pathol Pharmacol 1980;29;309-315.
51. Lissoni P, Tancini G, Paolorossi F, et al. Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. J Pineal Res 1999;26:169-173.
52. Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983;10:53-55.
53. Unverferth DV, Jagadeesh JM, Unverferth BJ, et al. Attempt to prevent doxorubicin induced acute human myocardial morphologic damage with acetylcysteine. JNCI 1983;71:917-920.
54. Olson RD, Stroo WE, Boerth RC. Influence of N-acetylcysteine on the antitumor activity of doxorubicin. Semin Oncol 1983;10:29-34.
55. Schmitt-Graff A, Scheulen ME. Prevention of adriamycin cardiotoxicity by niacin, isocitrate, or N-acetylcysteine in mice. Path Res Pract 1986;181:168-174.
56. Zhang K, Yang EB, Wong KP, Mack P. GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Int J Oncol 1999;14:861-867.
57. Cascinu S, Labianca R, Graziano F, et al. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer 1998;78:390-393.
58. Sadzuka Y, Sugiyama T, Hirota S. Modulation of cancer chemotherapy by green tea. Clin Cancer Res 1998;4:153-156.
59. Sugiyama T, Sadzuka Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett 1998;133:19-26.
60. Scambia G, Ranelletti FO, Panici PB, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994;34:459-464.
61. Critchfield JW, Welsh CJ, Phang JM, Yeh GC. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Biochem Pharm 1994;48:1437-1445.
62. Versantvoort CHM, Schuurhuis GJ, Pinedo HM, et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 1993;68:939-946.
63. Doyle LA, Giangiulo D, Hussain A. Differentiation of human variant small cell lung cancer cell lines to a classic morphology by retinoic acid. Cancer Res 1989;49:6745-6751.
64. Kalemkerian GP, Jiroutek M, Ettinger DS, et al. A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma. Cancer 1998;83:1102-1108.
65. Adwankar M, Banerji A, Ghosh S. Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. Tumori 1991;77:391-394.
66. Chiang CD, Song EJ, Yang VC, Chao CCK. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells. Biochem J 1994;301:759-764.
67. Lissoni P, Paolorossi F, Ardizzoia A. A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J Pineal Res 1997;23:15-19.
68. Ghielmini M, Pagani O, de Jong J. Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer. Br J Cancer 1999;80:1058-1061.
69. Weisman RA, Christen R, Los G, et al. Phase I trial of retinoic acid and cis-platinum for advanced squamous cell cancer of the head and neck based on experimental evidence of drug synergism. Otolaryngol Head Neck Surg 1998;118:597-602.
70. Prasad KN, Hernandez C, Edwards-Prasad J, et al. Modification of the effect of tamoxifen, cis-platin, DTIC. and interferon-alpha 2b on human melanoma cells in culture by a mixture of vitamins. Nutr Cancer 1994;22:233-245.
71. Sue K, Nakagawara A, Okuzono SI, et al. Combined effects of vitamin E (alphatocopherol) and cisplatin on the growth of murine neuroblastoma in vivo. Eur J Cancer Clin Oncol 1988;24:1751-1758.
72. Naganuma A, Satoh M, Imura N. Effect of selenite on renal toxicity and antitumor activity of cis-diamminedichloroplatinum in mice inoculated with Ehrlich ascites tumor cell. J Pharmacobiodyn 1984;7:217-220.
73. Berry JP, Pauwella C, Tlouzeau S, et al. Effect of selenium in combination with cis-diamminedichloroplatinum(II) in the treatment of murine fibrosarcoma. Cancer Res 1984;44:2864-2868.
74. Ohkawa K, Tsukada Y, Dohzono H, et al. The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumor activity. Br J Cancer 1988;58:38-41.
75. Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997;56:331-341.
76. Roller A, Weller M. Antioxidants specifically inhibit cisplatin cytotoxicity of human malignant glioma cells. Anticancer Res 1998;18:4493-4497.
77. Miyajima A, Nakashima J, Tachibana M, et al. N-acetylcysteine modifies cis-dichlorodiammineplatinum induced effects in bladder cancer cells. Jpn J Cancer Res 1999;90:565-570.
78. Sheikh-Hamad D, Timmins K, Jalali Z. Cisplatin-induced renal toxicity: possible reversal by N-acetylcysteine treatment. J Am Soc Nephrol 1997;8:1640-1644.
79. Smyth JF, Bowman A, Parren T, et al. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997;8:569-573.
80. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 1996;6:415-419.
81. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J Clin Oncol 1995;13:26-32.
82. Marverti G, Andrews PA. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res 1996;2:991-999.
83. Hofmann J, Fiebig HH, Winterhalter BR, et al. Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int J Cancer 1990;45:536-539.
84. Nagai Y, Horie T, Awazu S. Vitamin A, a useful biochemical modulator capable of preventing intestinal damage during methotrexate treatment. Pharmacol Toxicol 1993;73:69-74.
85. Milner JA, Hsu CY. Inhibitory effects of selenium on the growth of L1210 leukemic cells. Cancer Res 1981;41:1652-1656.
86. Furuya Y, Yamamoto K, Kohno N, et al. 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer cells (MCF7). Cancer Lett 1994;81:95-98.
87. Danysz A, Wierzba K, Wutkiewicz M, et al. Influence of some sulfhydryl compounds on the antineoplastic effectiveness of 5-fluorouracil and 6-mercaptopurine. Arch Immunol Ther Exp 1984;32:345-349.
88. Danysz A, Wierzba K, Pniewska A, et al. The effect of sulfhydryl compounds on 5-fluorouracil toxicity and distribution. Arch Immunol Ther Exp 1983;31:373-379.
89. Conley BA, Ramsland TS, Sentz DL, et al. Antitumor activity, distribution, and metabolism of 13-cis-retinoic acid as a single agent or in combination with tamoxifen in established human MCF-7 xenografts in mice. Cancer Chemother Pharmacol 1999;43:183-197.
90. Recchia F, Rea S, De Filippis S, et al. Beta-interferon, retinoids and tamoxifen combination in advanced breast cancer. Clin Ter 1998;149:203-208.
91. Budd GT, Adamson PC, Gupta M, et al. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 1998;4:635-642.
92. Guthrie N, Gapor A, Chambers AF, et al. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. J Nutr 1997;127:544S-548S.
93. Lissoni P, Barni S, Meregalli S, et al. Modulation of cancer endocrine therapy by melatonin: a phase II study on tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone. Br J Cancer 1995;71:854-856.